Skip to content
lifestyle.travelshq.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
AEON Biopharma Inc
AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450
September 30, 2026
AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX®
September 9, 2026
AEON Biopharma to Participate in Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference
August 31, 2026
AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer
August 24, 2026
AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®
August 19, 2026
AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 12, 2026
AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards
August 3, 2026
AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 14, 2026
AEON Biopharma Sets Annual Shareholder Meeting
April 24, 2026
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program
March 31, 2026
1
2
Next Page
→